natgillin/translations-raw huggingface dataset:
A complex comprising the peptide of any one of aspects 1-10 and a cargo molecule. 
Kompleksni spoj, koji sadrži peptid bilo kojeg patentnog zahtjeva 1-4 i molekulu tereta.
A composition for use as claimed in Claim 1, wherein the composition further comprises at least one of: a MASP-1 inhibitory agent, a MASP-2 inhibitory agent, a combination of a MASP-1 inhibitory agent and a MASP-2 inhibitory agent, and/or a terminal complement inhibitor that inhibits cleavage of complement protein C5. 
Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što pripravak dodatno sadrži najmanje jedno od: sredstva za inhibiranje MASP-I, sredstva za inhibiranje MASP-2, kombinaciju sredstva za inhibiranje MASP-I i sredstva za inhibiranje MASP-2, i/ili inhibitor terminalnog komplementa koji inhibira cijepanje komplementnog proteina C5.
Accordingly, a first aspect of the present invention relates to a pharmaceutical composition comprising a 1-benzyl-3-hydroxymethylindazole derivative, at least one of (i) a pressure lowering agent selected from ACE-inhibitors, renin inhibitors, ARBs, and CCBs and/or (ii) a cholesterol lowering agent selected from statin derivatives, or any pharmaceutically acceptable salt and ester thereof, and at least one pharmaceutically acceptable vehicle. 
OCH, (b) najmanje jedno od (i) sredstvo za smanjenje tlaka odabrano od ACE-inhibitora, od sredstava ARB i CCB, iili (ii) sredstvo za sniženje kolesterola odabrano od derivata statina, ili njihova bilo koja farmaceutski prihvatljiva sol i njihov takav ester, i
wherein: VLhB-B13 comprises the amino acid sequence of SEQ ID NO: 1, VLh8D4-8 comprises the amino acid sequence of SEQ ID NO: 3, VHhB-B13 comprises the amino acid sequence of SEQ ID NO: 2, and VHh8D4-8 comprises the amino acid sequence of SEQ ID NO: 4; or 
Izolirano protutijelo ili njegov fragment protutijela koji se specifično veže na IL-4, naznačeno time da protutijelo ili njegov fragment protutijela je humaniziran, te pri čemu protutijelo ili njegov fragment protutijela sadrži varijabilni lagani lanac koji sadrži sekvencu aminokiseline iz SEQ ID NO: 3 i sadrži varijabilni teški lanac koji sadrži sekvencu aminokiseline iz SEQ ID NO: 4.
The present invention furthermore relates to a method of treating a subject suffering from an immunoregulatory abnomality, comprising administering to said subject a compound of formula (I), and related formulae in an amount that is effective for treating said immunoregulatory abnormality. The present invention preferably relates to a method wherein the immunoregulatory abnormality is an autoimmune or chronic inflammatory disease selected from the group consisting of: allergic diseases, amyotrophic lateral sclerosis (ALS), systemic lupus erythematosus, chronic rheumatoid arthritis, type I diabetes mellitus, inflammatory bowel disease, biliary cirrhosis, uveitis, multiple sclerosis, Crohn's disease, ulcerative colitis, bullous pemphigoid, sarcoidosis, psoriasis, autoimmune myositis, Wegener's granulomatosis, ichthyosis, Graves ophthalmopathy and asthma. 
Spoj prema zahtjevu 7 naznačen time da je autoimuna bolest odabrana iz skupine koju čine astma, reumatoidni artritis, akutni diseminirani encefalomijelitis (ADEM), Addisonova bolest, alopecija areata, ankilozirajući spondilitis, sindrom antifosfolipidnih protutijela (APS), autoimuna hemolitička anemija, autoimuni hepatitis, autoimuna bolest unutarnjeg uha, bulozni pemfigoid, Behcetova bolest, celijakija, anti-transglutaminaza, Chagasova bolest, kronična opstruktivna plućna bolest, Crohnova bolest, dermatomiozitis, šećerna bolest tip 1, endometrioza, Goodpastureov sindrom, Gravesova bolest, Guillain-Barrć sindrom (GBS), Hashimotova bolest, Hidradenitis suppurativa, Kawasakijeva bolest, IgA nefropatija, idiopatska trombocitopenična purpura, intersticijski cistitis, eritemski lupus, miješana bolest vezivnog tkiva, morfea, multipla skleroza (MS), miastenija
The antibody, functional fragment thereof or antibody mimetic for use according to any one of claims 1 to 4 wherein the affinity reagent elicits one or more of antibody-dependent cellular cytotoxicity (ADCC),complement dependent cytotoxicity (CDC) and/or T-cell cytotoxicity. 
Antitijelo, njegov funkcionalni fragment ili mimetik antitijela za primjenu prema bilo kojem od zahtjeva 1 do 4, pri čemu afinitetni reagens pobuđuje jednu ili više staničnih citotoksičnosti ovisnih od antitijela (ADCC), citotoksičnosti ovisnih od komplementa (CDC) i/ili citotoksičnosti ovisnih od T-stanica.
The crystallization process comprises dissolving or suspending compactin in at least one water miscible organic solvent to form a reaction mixture; adding water to the reaction mixture, in a volume of about 0.16 to about 0.4 to the water miscible organic solvent; cooling the reaction mixture to a temperature until compactin crystallizes; and collecting the pure compactin crystals. 
Postupak kristalizacije uključuje otapanje ili suspendiranje kompaktina u najmanje jednom organskom otapalu koje se miješa s vodom, a kako bi nastala reakcijska smjesa; dodavanje vode u reakcijsku smjesu, u volumenu 0.16 do 0.4 prema organskom otapalu koje se miješa s vodom; hlađenje reakcijske smjese do temperature na kojoj kompaktin kristalizira; 1 sakupljanje čistih kristala kompaktina.
is a single bond, a carbonyl group, or a methylene group optionally substituted by a lower alkyl group; 
je jednostruka veza, karbonil skupina, ili metilen skupina po izboru supstituirana nižom alkilnom skupinom;
A compound of the formula (II-a): wherein Ring A, Ring B and Y are as defined in 1, and R11b, R11c and R11d are as defined in 22. 
gdje su Prsten A, Prsten B i Y definirani kao u patentnom zahtjevu 1, a R'* je atom broma ili atom joda, sa spojem boronske kiseline formule X:
Preferably, said disaccharide is an agent selected from the group consisting of sucrose, trehalose, maltose and/or lactose. 
Formulacija prema zahtjevu 6, naznačena time, da je navedeni disaharid takvo sredstvo koje je odabrano iz skupine koja se sastoji od sukroze i/ili trehaloze.
precipitating compound (I) from the reaction mixture; recrystallising the precipitate from a solvent selected from ethyl acetate, water, methanol, ethanol and isopropanol, so as to obtain compound (I) in crystalline form A; 
b) taloženjem spoja (I) iz reakcijske smjese; c) rekristalizacijom taloga 1z otapala odabranog između etil acetata, vode, metanola, etanola i izopropanola, tako da se dobije spoj (I) u kristaličnom obliku A; gdje je taj kristalični oblik A naznačen:
Cy1 is optionally further substituted by one to three independent occurrences of R6, wherein each occurrence of R6 is -OMe, methyl, ethyl, F, or Cl. 
Cy1 je izborno dalje supstituiran sa jednim do tri nezavisna R6, pri čemu je svaki R6 jednak -OMe, metil, etil, F ili Cl.
The receiver includes, or is connected to, an acoustic transducer, or its equivalent, for sounding an alarm when radio communication between the transmitter and receiver is broken. 
Prijemnik uključuje, ili je na njega spojen, akustični davač, ili njegov ekvivalent, u cilju davanja zvučnog alarma u slučaju prekida radio veze između odašiljača i prijemnika.
A liquid formulation containing luteinizing hormone (LH) or a variant thereof characterized in that said formulation comprises a phosphate buffer and a stabilizing amount of arginine or salts thereof at a concentration of 10 to 50 mg/ml and/or lysine or salts thereof at a concentration of 10 to 50 mg/ml. 
HR P20120660 T1 PATENTNI ZAHTJEVI Tekuća formulacija koja sadrži luteinizirajući hormon (LH) ili njegovu varijantu naznačena time da navedena formulacija sadrži fosfatni pufer 1 stabilizirajuću količinu arginina ili njegovih soli u koncentraciji od 10 do 50 mg/ml i/ili lizina ili njegovih soli u koncentraciji od 10 do 50 mg/ml.
Rigidity can also be imparted electrostatically. 
Krutost se također može povećati elektrostatski.
D/E-X-N-Z-S/T, wherein X and Z may be any natural amino acid except Pro, wherein et least one of said N-glycosylated optimized amino acid consensus sequence(s) is recombinantly introduced into said protein, and wherein said protein is P. aeruginosa exoprotein. 
Uporaba jedne ili više sekvenci aminokiselina koje sadrže sekvencu D/E- X- N-Z-S/T, gdje X i Z mogu biti bilo koja prirodna aminokiselina osim prolina, za modificiranje proteina tako da oligosaharil transferaza iz Campylobacter spp. može taj protein N-glikozilirati.
The solid system for use in accordance with claim 9 or 10, wherein the solid system is in form of a tablet and the active ingredient is contained in microgranules or microcapsules dispersed in the polymeric matrix. 
Čvrsti sustav za upotrebu u skladu sa patentnim zahtjevom 9 ili 10, naznačen time što čvrsti sustav je u obliku tablete i aktivni sastojak je sadržan u mikrogranulama ili mikrokapsulama disperziranim u polimernom matriksu.
Use of the polymorphic Form B of N-[4-(trifluoromethyl)benzyl]-4-methoxybutyramide according to claim 1 or 2 for the manufacture of a medicament in the treatment of drug addiction and alcoholism. 
Polimorfni oblik A N-[4-(trifluorometil)benzil]-4-metoksibutiramida, u skladu sa zahtjevima 1 ili 2, za primjenu u terapiji ovisnosti od narkotika i alkoholizma.
After this time, the solution was cooled to RT and diluted with ethyl acetate. 
Nakon ovog vremena otopina je ohlađena na sobnu temperaturu i razrijeđena sa etil acetatom.
The method of para 19, further comprising the step of sequencing said amplified CRISPR locus sequence and said amplified modified CRISPR sequence locus. 
Postupak prema zahtjevu 8, naznačen time da dodatno sadrži korak sekvenciranja navedene umnožene CRISPR lokus sekvence i navedene umnožene modificirane CRISPR lokus sekvence.
The method of claim 28, wherein the inflammatory disease or disorder is selected from sinusitis, pneumonitis, osteomyelitis, gastritis, enteritis, gingivitis, appendicitis, irritable bowel syndrome, tissue graft rejection, chronic obstructive pulmonary disease (COPD), septic shock, toxic shock syndrome, SIRS, bacterial sepsis, osteoarthritis, acute gout, acute lung injury, acute renal failure, burns, Herxheimer reaction, and SIRS associated with viral infections. 
Spoj ili pripravak za uporabu prema patentnom zahtjevu 28, naznačen time, da se akutni ili kronični ne-autoimuni upalni poremećaj bira iz sinusitisa, pneumonitisa, osteomijelitisa, gastritisa, enteritisa, gingivitisa, apendicitisa, sindroma iritabilnog kolona, odbacivanja presadka, kronične opstrukcijske plućne bolesti (COPD, prema engl. „ chronic obstructive pulmonary disease“), septičkog šoka, osteoartritisa, akutnog gihta, akutne ozljede pluća, akutnog zatajenja bubrega, opeklina, Herxheimerove reakcije, i sindroma sustavnog upalnog odgovora (SIRS, prema engl. „systemic inflammatory response syndrome“) povezanog s virusnim infekcijama.
wherein W1 represents a suitable leaving group and wherein the variables are as defined in claim 1. A process to prepare a compound according to claim 1 characterized by reacting an intermediate of formula (II-a), (II-b), (II-c) or (II-d) with a suitable acid, wherein R1, R2, R3, R3a, R4, R5, R6, R7 R8 R9, p and q are as defined in claim 1; 
Spoj formule njegova farmaceutski prihvatljiva sol, njegova N-oksidna forma ili njegov solvat, naznačeni time da W, predstavlja pogodnu odlaznu grupu i pri čemu su varijable kako je definirano u patentnom zahtjevu 1. HR P20100428 T1 27. Postupak za pripremu spoja prema patentnom zahtjevu 1, naznačen time da se sastoji od: a) reakcije intermedijera formule (II-a), (1I-b), (II-c) ili (II-d) sa pogodnom kiselinom, kiselina kiselina
The medium further contained all amino acids but for Glutamine. 
Medij je nadalje sadržavao sve aminokiseline osim glutamina.
Process according to claim 1, CHARACTERIZED wherein the alkali in step (a) is chosen from the group consisting of sodium hydroxide, potassium hydroxide, lithium hydroxide, magnesium hydroxide and their mixtures, and the weight ratio of alkali to crude or refined oil is approximately 0.15:1 and the weight ratio of water to crude or refined oil is between 0.5:1 and 2:1. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što se alkalija u koraku (a) bira iz skupine koju čine natrijev hidroksid, kalijev hidroksid, litijev hidroksid, magnezijev hidroksid i njihove smjese, težinski omjer između alkalije 1 sirovog ili rafiniranog ulja je približno 0,15:1, a težinski omjer između vode 1 sirovog ili rafiniranog ulja je između 0,5:1 12:1.
deformylating the compound of Formula XXV to give the compound of Formula XXVI,. wherein 
e. < deformilaciju spoja Formule XXV, čime se dobiva spoj Formule XXVI:
µL assay buffer for total binding or 
- < 25 ul pokusnog pufera za ukupno vezanje, ili
The method according to paragraph 3 in which the initial dose ranges is from 0.1 mg/kg to 1 mg/kg of rhASM. 
() primjenu incijalne niske netoksične doze KSM, pri čemu je navedena inicijalna doza raspona od 0,05 mg/kg do 0,275 mg/kg KSM-a;
Referring to the drawings, which depict a non-limiting example of the preferred embodiment of the invention, a jar 10 comprises a hollow, cylindrical housing 11 typically manufactured from a high grade steel or any of a range of other materials commonly used in the manufacture of downhole tools. 
Pozivajući se na crteže, koji predstavljaju neograničavajući primjer prema izumu, udarac 10 sadrži šuplje cilindrično kućište 11 koje je uobičajeno izgrađeno od visokokvalitetnog čelika ili bilo kojeg drugog materijala koji se koristi za proizvodnju bušaće garniture.
R1, R2, R3, and U may have protecting group(s) required for the synthesis. 
, R2, R3 i U mogu imati jednu ili više zaštitnih skupina, potrebnih u sintezi.
the amount of dissolved oxygen (dO2) in the pre-harvest or harvested culture fluid is at least about 10% or is at least about 30%. 
Postupak prema patentnom zahtjevu 3, naznačen time, da se propuhivanje zrakom nastavlja sve dok količina otopljenog kisika (dO2) u sakupljenom fluidu stanične kulture ne bude najmanje 10%.
A method of treating inflammatory conditions and immune or anaphylactic disorders associated with infiltration of leukocytes into inflamed tissue in a subject in need thereof which comprises administering to said subject a therapeutically effective amount of the compound of claim 1 or 2 or 20. 
Upotreba spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 32, ili njegove farmaceutski prihvatljive soli ili solvata, u proizvodnji medikamenta za liječenje upalnih stanja i imunosnih ili anafilaktičkih poremećaja povezanih s infiltracijom leukocita u upaljeno tkivo.
The sidewall construction of a casting mold according to claim 1, wherein the support construction is formed of a form profile. 
Konstrukcija bočnog zida kalupa za lijevanje prema zahtjevu 1, naznačena time, da je potporna konstrukcija formirana od oblika profila.
subjecting the extract obtained at step c) to size-exclusion ultrafiltration with a molecular weight membrane cut-off of 30kDa; collecting the retentate. 
podvrgavanjem ekstrakta dobivenog u koraku c) ultrafiltraciji metodom isključenja po veličini uz membranu granične molekulske mase 30 kDa;
is hydrogen, alkyl, alkoxyalkyl, alkylcarbonyl, alkylthiocarbonyl or unsubstituted or substituted benzyl, whereby the substituents may each be independent of one another and are selected from the group consisting of cyano, nitro, halogen, alkyl, haloalkyl, alkylthio, haloalkylthio, arylthio, alkoxy, haloalkoxy, alkylcarbonyl, haloalkylcarbonyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, alkylamino, di(alkyl)amino; 
Rgje vodik, alkil, alkoksialkil, alkilkarbonil, alkiltiokarbonil ili nesupstituirani ili supstituirani benzil, gdje supstituenti mogu biti svaki neovisan jedan od drugoga i odabrani su iz skupine koja se sastoji od sljedećih: cijano, nitro, halogen, alkil, haloalkil, alkiltio, haloalkiltio, ariltio, alkoksi, haloalkoksi, alkilkarbonil, haloalkilkarbonil, alkilsulfinil, haloalkilsulfinil, alkilsulfonil, haloalkilsulfonil, alkilamino, di(alkil)amino;
An active compound combination according to claim 1 wherein the compound (A) of formula (I) is selected from the group consisting of: 
2. < Aktivni pripravak prema zahtjevu 1 naznačen time da je spoj (A) s formulom (I) odabran iz skupine koju čine:
A nucleic acid encoding a T-cell receptor (TCR) according to Claim 25 or 26. An expression vector capable of expressing a T-cell receptor (TCR) according to Claim 25 or 26. 
Nukleinska kiselina koja kodira receptor T stanica (TCR) prema Zahtjevu 17 ili vektor ekspresije sposoban za ekspresiju spomenutog receptora T stanice (TCR).
The use of 3, 11b- cis -dihydrotetrabenazine for the manufacture of a medicament for preventing, alleviating or reducing one or more symptoms of schizophrenia. A method for preventing, alleviating or reducing one or more symptoms of schizophrenia, the method comprising administering to the mammal a therapeutically effective amount of cis -dihydrotetrabenazine. The psychotic episodes, psychoses or symptoms prevented, alleviated or reduced in accordance with the invention may be any one or more symptoms selected from: 
* - Uporabu 3,11b-cis-dihidrotetrabenazin Izomera A za pripremu lijeka za prevenciju, ublažavanje ili smanjivanje jednog ili više simptoma šizofrenije. Psihotične epizode, psihoze ili simptomi koji su spriječeni, ublaženi ili smanjeni u skladu s izumom, mogu biti bilo koji ili više njih, izabranih iz skupine koju čine: iluzije; halucinacije; vizualne halucinacije; slušne halucinacije; halucinacije koje sadržavaju taktilne doživljaje, okuse ili mirise; zbunjenost; emocionalni ili intelektualni poremećaji ili poremećaji ponašanja; odmak od stvarnosti; nelogičan i/ili neorganiziran oblik razmišljanja; paranoidna ili iluzijska vjerovanja;
An HIV gp140 trimer comprising an HIV gp140 polypeptide comprising an amino acid sequence at least 95% identical to the sequence: comprising a trimerization domain; and comprising a variable loop V3 peptide; 
HIV gp140 trimer koji obuhvaća HIV gp140 polipeptid koji sadrži sekvencu aminokiselina najmanje 95% identično sekvenci:
The therapeutic agent according to claim 13, wherein the disease with a highly expressed human CDH3 is selected from breast cancer, lung cancer, colon cancer, or panvreatic cancer. 
Terapijsko sredstvo, namijenjeno upotrebi u skladu s patentnim zahtjevom 11, naznačeno time što se bolest kod koje se visoko eksprimira ljudski CDH3 bira između raka dojke, raka pluća, raka debelog crijeva ili raka gušterače.
An antibody which is capable of binding to Interleukin 11 (IL-11) or IL-11 receptor a (IL-11Ra) and inhibiting IL-11 mediated signalling, for use in a method of treating or preventing Crohn's disease, microscopic colitis or primary sclerosing cholangitis (PSC). 
Protutijelo za uporabu u postupku liječenja ili prevencije fibroze prema zahtjevu 1, naznačeno time, da je protutijelo sposobno za prevenciju ili redukciju vezivanja IL-11 na IL-11 receptor.
One or several binders according to the invention are preferably selected from the group consisting of polyvidone (used synonymously for povidone), methylcellulose, hydroxypropylmethylcellulose (HPMC), hydroxymethylcellulose, starch, gelatine, and the like. 
Kruti pripravak prema zahtjevu 1 ili 2, naznačen time, da je vezivo odabrano iz skupine koju čine polividon/povidon, metilceluloza, hidroksipropilmetilceluloza (HPMC), hidroksimetilceluloza, škrob i želatina.
where the compound of formula (I) contains a secondary amino group, a primary derivative thereof (—NHRa→—NH2); 
GV) dok nakon toga slijedi reakcija s aminom HN(R!)(R*) za dobivanje spoja formule (I);
The compound according to claim 29 or a pharmacologically acceptable salt thereof, wherein the prodrug group represented by R4 is a benzyl group or a [(isopropoxycarbonyl)oxy]ethyl group. 
Spoj u skladu sa patentnim zahtjevom 23 ili njegova farmakološki prihvatljiva sol, gdje je prolijek grupa predstavljena sa R4 benzil grupa ili [(izopropoksikarbonil)oksi]etil grupa.
R1-R2 are independently selected from hydrogen, C1-6-alk(en/yn)yl, C3-8-cycloalk(en)yl, and C3-8-cycloalk(en)yl-C1-6-alk(en/yn)yl; or R1 and R2 together with the nitrogen form a 4-7 membered ring containing zero or one double bond, optionally said ring in addition to said nitrogen comprises one further heteroatom selected from nitrogen, oxygen and sulphur; 
. (m u kojima R-R* su nezavisno izabrani iz vodika C,.s-alk(en/in)il, C3g-cikloalk(en)il i Cg.g-cikloalk(en)il-C;.g-alk(en/in)il; ili Ri R* zajedno s dušikom tvore 4-7-člani prsten koji sadrži nula ili jednu dvostruku svezu a, opcionalno, rečeni prsten, uz rečeni dušik, sadrži ijedan heteroatom izabran iz dušika, kisika i sumpora;
After two hours, the reaction mixture was cooled and filtered. 
Nakon dva sata, reakciona smjesa se hladi i filtrira.
The combination for the use according to claim 1, wherein 
Kombinacija za uporabu u skladu s patentnim zahtjevom 1, naznačena time, da
A method according to claim 1 wherein the polymer matrix comprises a linear polylactide-co-glycolide polymer and a star polylactide-co-glycolide polymer having a weight average molecular weight of about 50,000 Da. 
Mikročestice u skladu sa zahtjevom 2, naznačene time, da polimerni matriks sadrži Resomer" RG polimer i zvjezdasti polilaktid-ko-glikolid polimer koji ima težinsku prosječnu molekularnu masu od oko 50.000 Da.
The crude product was purified by flash chromatography on silica gel (eluent: ethyl acetate/heptane 2:8) to produce the target compound as a white foam, yield: 4.53 g (57%). 
Sirovi proizvod je pročišćen flash kromatografijom na silikg gelu (eluent: etil acetat/heptan 2:8) te se dobio traženi spoj u obliku bijele pjene; iskorištenje 4.53 g (57%I0).
The G-CSF may be recombinant bovine or human G-CSF, it can be bovine or human methionyl-G-CSF. 
Postupak u skladu s patentnim zahtjevom 1 ili 2, naznačen time što je G-CSF rekombinantni goveđi ili ljudski metionil-G-CSF.
The method according to claim 1, wherein a damp-proof membrane is fitted beneath the floor structure. The method according to claim 8, wherein the damp-proof membrane extends at least partly up the opposed external wall structures of the building. The method according to claim 1, wherein the insulating layer in the roof structure is provided within a ceiling structure or within a sloping roof structure. 
Zgrada prema bilo kojem od zahtjeva 6 do 12, koja ispod podne konstrukcije uključuje jednu membranu za izolaciju od vlage (62) koja se opcionalno proteže djelomično prema gore po zidovima zgrade. Zgrada prema bilo kojem od zahtjeva 6 do 13, kod koje je izolacijski sloj (86) u krovnoj konstrukciji (50) postavljen unutar stropne konstrukcije (20) ili unutar kose krovne konstrukcije.
Use of methyl iso -butyl ketone for removing ethylene glycol from the compound of formula I-2 as defined in claim 1 when said compound is obtained by the reaction of the compound of formula I-1 as defined in claim 1 with ethylene glycol in the presence of a base. 
Uporaba metil-izo-butil-ketona, naznačena time, da je za odstranjivanje etilen-glikola iz spoja formule I2 kako je definirano u zahtjevu 1, kada se navedeni spoj dobiva pomoću reakcije spoja formule I1 s etilen-glikolom u prisutnosti lužine, kako je definirano u zahtjevu 1.
a C1-10 alkylsulfonyl group which can be substituted, a C3-7 cycloalkyl group which can be substituted, 
C1-10 alkilsulfonil-skupina koja može biti supstituirana; C3-7 cikloalkil-skupina koja može biti supstituirana;
Rotarod training, 2 sessions at 1 hour interval 
Rotarod trening, 2 niza u jednosatnom intervalu
with a compound H-E under basic conditions wherein E is as defined for general formula (I) in claim 1; or carrying out a process selected from processes (A) and (B) followed by interconversion of one or more functional groups. 
\ s Rong G2 s reagensom pogodnim za uvođenje skupine E; ili (C) provedbi postupka kojeg se bira između postupaka (A) i (B), te interkonverziji jedne ili više funkcionalnih skupina.